Dix; Daniel B.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Dix; Daniel B..The latest application filed is for "stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies".

Company Profile

10.18.28

Dix; Daniel B. - LaGrangeville NY
DIX; Daniel B. - Rensselaer NY

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies App 20210403581 - Dix; Daniel B. ; et al.	2021-12-30
VEGF Antagonist Formulations App 20210393530 - DIX; Daniel B. ; et al.	2021-12-23
VEGF Antagonist Formulations App 20210393778 - DIX; Daniel B. ; et al.	2021-12-23
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies Grant 11,098,127 - Dix , et al. August 24, 2	2021-08-24
VEGF Antagonist Formulations App 20210252147 - DIX; Daniel B. ; et al.	2021-08-19
VEGF Antagonist Formulations App 20210252105 - DIX; Daniel B. ; et al.	2021-08-19
Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies App 20210230283 - Dix; Daniel B. ; et al.	2021-07-29
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies Grant 11,059,896 - Dix , et al. July 13, 2	2021-07-13
VEGF Antagonist Formulations App 20210077624 - DIX; Daniel B. ; et al.	2021-03-18
Stabilized Formulations Containing Anti-pcsk9 Antibodies App 20210054100 - WALSH; Scott M. ; et al.	2021-02-25
Formulations of VEG antagonist fusion proteins and method of manufacturing them Grant 10,857,231 - Dix , et al. December 8, 2	2020-12-08
Stabilized formulations containing anti-PCSK9 antibodies Grant 10,752,701 - Walsh , et al. A	2020-08-25
Devices And Methods For Overfilling Drug Containers App 20200155760 - DIX; Daniel B. ; et al.	2020-05-21
Method Of Manufacturing Vegf Antagonist Fusion Proteins App 20190388539 - DIX; Daniel B. ; et al.	2019-12-26
Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies App 20190367624 - Dix; Daniel B. ; et al.	2019-12-05
Stabilized formulations containing anti-PCSK9 antibodies Grant 10,472,425 - Walsh , et al. Nov	2019-11-12
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies Grant 10,435,473 - Dix , et al. O	2019-10-08
Stabilized Formulations Containing Anti-pcsk9 Antibodies App 20190284301 - WALSH; Scott M. ; et al.	2019-09-19
Method of manufacturing VEGF antagonist fusion proteins Grant 10,406,226 - Dix , et al. Sept	2019-09-10
Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies App 20190002574 - Dix; Daniel B. ; et al.	2019-01-03
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies Grant 10,072,086 - Dix , et al. September 11, 2	2018-09-11
Stabilized Formulations Containing Anti-PCSK9 Antibodies App 20180044436 - Walsh; Scott M. ; et al.	2018-02-15
Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies App 20180002426 - Dix; Daniel B. ; et al.	2018-01-04
Vegf Antagonist Formulations App 20170360930 - DIX; Daniel B. ; et al.	2017-12-21
VEGF specific fusion protein antagonist formulations Grant 9,636,400 - Dix , et al. May 2, 2	2017-05-02
Vegf Antagonist Formulations App 20170073407 - DIX; Daniel B. ; et al.	2017-03-16
VEGF antagonist formulations suitable for intravitreal administration Grant 9,580,489 - Furfine , et al. February 28, 2	2017-02-28
Vegf Antagonist Formulations Suitable For Intravitreal Administration App 20160244505 - FURFINE; Eric ; et al.	2016-08-25
Vegf Antagonist Formulations App 20160244504 - DIX; Daniel B. ; et al.	2016-08-25
Stabilized formulations containing anti-Ang2 antibodies Grant 9,402,898 - Walsh , et al. August 2, 2	2016-08-02
Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies App 20160102147 - Dix; Daniel B. ; et al.	2016-04-14
Stabilized Formulations Containing Anti-PCSK9 Antibodies App 20160032015 - Walsh; Scott M. ; et al.	2016-02-04
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies Grant 9,238,692 - Dix , et al. January 19, 2	2016-01-19
Stabilized Formulations Containing Anti-Interleukin-6 Receptor (IL-6R) Antibodies App 20160002341 - Dix; Daniel B. ; et al.	2016-01-07
Stabilized formulations containing anti-PCSK9 antibodies Grant 9,193,801 - Walsh , et al. November 24, 2	2015-11-24
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies Grant 9,173,880 - Dix , et al. November 3, 2	2015-11-03
Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies App 20150100030 - Dix; Daniel B. ; et al.	2015-04-09
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies Grant 8,945,559 - Dix , et al. February 3, 2	2015-02-03
Stabilized Formulations Containing Anti-PCSK9 Antibodies App 20140341928 - Walsh; Scott M. ; et al.	2014-11-20
Stabilized Formulations Containing Anti-Ang2 Antibodies App 20130186797 - WALSH; Scott M. ; et al.	2013-07-25
Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies App 20120097565 - DIX; Daniel B. ; et al.	2012-04-26
Stabilized Formulations Containing Anti-Interleukin-6 (IL-6) Antibodies App 20110171241 - DIX; Daniel B. ; et al.	2011-07-14

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.